GlassScriptPhysician profile
Jason A Rolls
NPI 1245497478
$50,986.38
in general payments reported to CMS, 2019-2025
12 companies · $50K in 2025
The $50K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2021: $83.73 · 2022: $46.01 · 2023: $233 · 2024: $227 · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $49K · Food and Beverage: $873 · Travel and Lodging: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $49,108.51 |
| Food and Beverage | $873.38 |
| Travel and Lodging | $707.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $49,815.67 | 2025 | |
| Organ Recovery Systems, INC. | $260.09 | 2025 | |
| Veloxis Pharmaceuticals, INC. | $153.92 | 2019-2025 | Envarsus |
| Sanofi-Aventis U.S. LLC | $142.38 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.93 | 2022-2023 | Livtencity |
| E.R. Squibb & Sons, L.L.C. | $117.59 | 2019 | |
| Medtronic, INC. | $84.79 | 2024 | Ellipsys Vascular Access System |
| Astrazeneca Pharmaceuticals LP | $83.73 | 2021 | |
| Ethicon US, LLC | $79.53 | 2023 | Echelon; Endopath, Vistaseal, Stratafix |
| Merck Sharp & Dohme LLC | $60.54 | 2023-2025 | Prevymis |
| Mozarc Medical US LLC | $38.17 | 2023 | Argyle |
| Otsuka America Pharmaceutical, INC. | $27.04 | 2025 | Voyxact |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Rolls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.